Lipohypertrophy and Insulin: An Update From the Diabetes Technology Society

Lipohypertrophy is a common skin complication associated with insulin-treated diabetes. The impact of lipohypertrophy as a contributing factor to suboptimal glycemic control, glucose variability, and hypoglycemia is often under-recognized by health care professionals. In a recent Webinar on April 26, 2023, Diabetes Technology Society asked international experts to provide updates on the latest knowledge related to lipohypertrophy for practicing clinicians and educators, researchers, and industries involved in insulin delivery. A recording of the Webinar is freely available on the Diabetes Technology Society Web site (https://www.diabetestechnology.org/).

Automated summary

Lipohypertrophy is a common skin complication in insulin-treated diabetes that is often underestimated as a contributing factor to suboptimal blood sugar control, glucose variability, and hypoglycemia. In a recent Webinar by the Diabetes Technology Society, international experts provided updates on the latest knowledge related to lipohypertrophy for clinicians, educators, researchers, and insulin delivery industries. The recorded session of the Webinar is freely available on the Diabetes Technology Society Web site (https://www.diabetestechnology.org/).